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ABSTRACT 
Heme oxygenase-1 (HO-1) transgenic mice (Tg) were created using a rat HO-1 genomic 
transgene. Transgene expression was detected by RT-PCR and Western blots in the left 
ventricle (LV), right ventricle (RV), and septum (S) in mouse hearts, and its function was 
demonstrated by the elevated HO enzyme activity. Tg and nontransgenic (NTg) mouse hearts 
were isolated and subjected to ischemia/reperfusion. Significant postischemic recovery in 
coronary flow (CF), aortic flow (AF), aortic pressure (AOP), and first derivative of AOP 
(AOPdp/dt) were detected in the HO-1 Tg group compared to the NTg values. In HO-1 Tg hearts 
treated with 50 µmol/kg of SnPPIX, an HO enzyme inhibitor, abolished the postischemic 
cardiac recovery. HO-1 related CO production was detected in NTg, HO-1 Tg, and HO-1 Tg 
+ SnPPIX treated groups, and a substantial increase in CO production was observed in the 
HO-1 Tg hearts subjected to ischemia/reperfusion. Moreover, in ischemia/reperfusion-
induced tissue Na+ and Ca2+ gains were reduced in HO-1 Tg group in comparison with the 
NTg and HO-1 Tg + SnPPIX treated groups, furthermore K+ loss was reduced in the HO-1 Tg 
group. The infarct size was markedly reduced from its NTg control value of 37±4% to 20±6% 
(p<0.05) in the HO-1 Tg group, and was increased to 47±5% (p<0.05) in the HO-1 KO hearts. 
Parallel to the infarct size reduction, the incidence of total and sustained VF were also 
reduced from their NTg control values of 92% and 83% to 25% (p<0.05) and 8% (p<0.05) in 
the HO-1 Tg group, and were increased to 100% and 100% in HO-1 knock out (-/-) hearts. 
Immunohistochemical staining of HO-1 was intensified in HO-1 Tg compared to the NTg 
myocardium. Thus, the HO-1 Tg mouse model suggests a valuable therapeutic approach in 
the treatment of ischemic myocardium.
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INTRODUCTION 
 
With respect to gene control and regulation, a great number of inducer-responsive 
elements have been identified and characterized within the 5’-flanking regions of the mouse, 
rat, and human heme oxygenase-1 (HO-1). In the past decades, substantial progress has been 
made in our understanding of the regulation and function of HO-1 and its isozymes. Thus, 
heat shock proteins including HO-1, known as 32-kDa stress-inducible protein (HSP-32), 
provides significant protection against a variety of tissue injuries [1]. Different isozymes of 
HO have been identified, cloned, and studies demonstrated that HO-1 is induced in response 
to various interventions causing oxidative stress including ultraviolet irradiation, hypoxia, and 
ischemia [2-6]. By degrading oxidant heme and generating antioxidant bilirubin, and a 
gaseous molecule, endogen carbon monoxide (CO), and HO-1 induction protect tissues from 
death caused by various pathological processes [7-10]. Thus, in various diseases that are 
induced by different factors, the lack of HO-1 or its expression substantially modifies tissue 
and organ functions. Given the cytoprotective role of HO-1, there is a growing interest in the 
importance of HO-1 and its byproducts e.g., iron and endogenous CO, in the recovery of 
cardiac injury caused by ischemia [11,12]. 
In our previous studies, we observed a reduction in HO-1 mRNA and protein 
expression causing decreased enzyme activity leading ultimately to poor recovery of the 
ischemic/reperfused fibrillated myocardium [13,14]. To conclusively demonstrate whether 
HO-1 plays a critical role in the recovery of postischemic myocardium, we generated HO-1 
transgenic mice. We hypothesized that the vulnerability of HO-1 transgenic mice to reduce 
the incidence of VF, attenuation of infarct size, and improved recovery of postischemic 
function during ischemia/reperfusion injury would be related to HO-1 protein expression and 
its byproducts including the endogenous CO or iron. We also speculated that HO-1 signaling 
and protein expression would play an essential role in the improvement postischemic cardiac 
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aortic flow, coronary flow, aortic pressure, the first derivative of aortic pressure, myocardial 
ion contents including Na+, K+, and Ca2+. Various mechanisms have been proposed to explain 
the postischemic recovery and the causes of arrhythmias, but relatively little attention has 
been paid, to our knowledge, in order to clarify the mechanism(s) of VF at a gene expression 
level in ischemic/reperfused hearts. For instance, the long QT syndrome and idiopathic 
ventricular fibrillation, as known up to now, are cardiac disorders based on genetic mutation 
of potassium channels and cause sudden cardiac death from ventricular arrhythmias [15-17]. 
The aim of our present study was to generate and use HO-1 transgenic mice to directly 
analyze the impact and role of HO-1 on postischemic recovery in the myocardium. In some 
additional studies, we made attempt to estimate the incidence of reperfusion-induced VF and 
infarct size in HO-1 Tg mouse heart in comparison with HO-1 knock out (-/-) and wild type 
mouse myocardium. We believe that the present study provides novel insights into the 
function of HO-1 and its contribution to the recovery of postischemic cardiac function and 
reduction of arrhythmias in the heart.  
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METHODS 
Transgenic mice: 
Transgenic mice were generated as described by Araujo et al. [9]. In brief, CFY mouse 
eggs were injected with 52 kb rat HO-1 construct containing 27.7 kb of the 5’ upstream 
region, 8.3 kb of HO-1 gene, and 16 kb of the 3’ downstream region. Cloning was carried out 
by PCR of rat genomic P1 library with two sets of PCR primers corresponding to the first 
exon (5’-GCT-TCG-GTG-GGT-TAT-CTG-CCG-TTA-T-3’ and 5’-CAG-TCT-TAC-AGG-
CGG-GGA-ATG-TGA-G-3’), and the 5th exon of rat HO-1 gene (5’-GAG-ACG-CCC-CGA-
GGA-AAA-TCC-CAG-AT-3’ and 5’-CCC-AAG-AAA-AGA-GAG-CCA-GGC-AAG-AT-
3’). Two clones were identified as positives, and restriction mapping showed that both of 
them included the same insert. The 52 kb band was equivalent to the HO-1 gene and flanking 
regions. This 52 kb fragment, including the native HO-1 gene and its promoter, was excised 
and digested with beta-agarase, and then microinjected. Mice were genotyped by PCR using 
the set of primers specific for rat HO-1 exon 5. 
 
Animals and heart preparation: 
Male wild type (nontransgenic, NTg), HO-1 transgenic, and HO-1 KO (-/-) mice (25-
35 g) (Charles Rivers Laboratories),  were used for all studies. Animals received humane care 
in compliance with the “Principles of Laboratory Animal Care” formulated by the National 
Society for Medical Research and the Guide for the Care and Use of Laboratory Animals 
prepared by the National Academy of Sciences and published by the National Institute of 
Health (NIH Publication No. 86-23, revised 1996). Mice were anaesthetized with 60 mg/kg of 
pentobarbital sodium. After i.p. administration of heparin (1,000 IU/kg) the chest was opened, 
the heart was rapidly excised and mounted to a “working” perfusion apparatus described by 
Hewett et al [18]. The perfusion was established with a modified oxygenated Krebs-Henseleit 
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buffer with the following concentrations (in mM): 118.4 NaCl, 4.1 KCl, 2.5 CaCl2, 25 
NaHCO3, 1.17 KH2PO4, 1.46 MgCl2, and 11.1 glucose. The perfusion buffer was previously 
saturated with a mixture of 95% O2 and 5% CO2, pH 7.4 at 37 °C. To prevent the 
myocardium from drying out, the heart chamber, in which hearts were suspended, was 
covered and the humidity was kept at a constant level (90%-95%). In all experiments global 
ischemia was induced for 20 min followed by 2 hours of reperfusion. In additional 
experiments, mice were i.p. injected with 50 µmol/kg of tin protoporphyrin IX (SnPPIX), an 
HO enzyme inhibitor, one day prior to the isolation of the heart and induction of ischemia and 
reperfusion. HO enzyme activities and recovery of postischemic cardiac function were 
measured in hearts obtained from NTg, HO-1 Tg, and HO-1 Tg-SnPPIX treatred mice. The 
schematic presentation of the experimental time course and parameters measured are shown 
in Figure 1.  
 
Registration of VF and measurement of cardiac function: 
Epicardial electro cardiograms (ECGs) were recorded throughout the experimental period 
by two silver electrodes attached directly to the heart and connected to a data acquisition system 
(ADInstruments, Powerlab, Castle Hill, Australia). ECGs were analyzed to determine the 
presence or absence of ventricular fibrillation (VF). Hearts were considered to be in VF if an 
irregular undulating baseline was apparent on ECGs. If the duration of VF was longer than 2 
min, the VF was defined as sustained VF, otherwise, the VF was nonsustained. If VF developed 
and the sinus rhythm did not spontaneously return within the first two min of reperfusion, hearts 
were electrically defibrillated by a defibrillator using two silver electrodes and 15 V square-wave 
pulse of 1 ms duration and reperfused. Aortic and coronary flow rates were measured by a timed 
collection of the aortic and coronary effluents that dripped from the heart. Before ischemia and 
during reperfusion, heart rate (HR), coronary flow (CF) and aortic flow (AF) were registered. 
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Aortic pressure (AOP), and the first derivative of aortic pressure (AOPdp/dt) were measured 
by a computer acquisition system (ADInstruments, Powerlab, Castle Hill, Australia).  
 
 Measurement of infarct size: 
 Infarct size was measured, at the end of each experiment, with 10 ml of 1 % triphenyl 
tetrazolium (TTC) solution in phosphate buffer (Na2HPO4 88 mM, NaH2PO4 1.8 mM) injected 
via the side arm of the aortic cannula then stored at -70 oC for later analysis. Frozen hearts were 
sliced transversely [19] in a plane perpendicular to the apico-basal axis into 1-2 mm thick 
sections, weighted, blotted dry, placed in between microscope slides and scanned on a 
Hewlett-Packard Scanjet 5p single pass flat bed scanner (Hewlett-Packard, Palo Alto, CA). 
Using the NIH Image 1.61 image processing software, each digitized image was subjected to 
equivalent degrees of background subtraction, brightness and contrast enhancement for 
improved clarity and distinctness. Infarct zones of each slice were traced and the respective 
areas were calculated in terms of pixels [20]. The areas were measured by computerized 
planimetry software and these areas were multiplied by the weight of each slice, then the 
results summed up to obtain the weight of the risk zone (total weight of the left ventricle, mg) 
and the infarct zone (mg). Infarct size was expressed as the ratio, in percent, of the infarct 
zone to the risk zone. 
 
 Northern blots and RT-PCR: 
 RNA was prepared from the left and right ventricles, and septum (about 50 mg) by 
guanidine isothiocyanate acid/phenol method [21], and 5 µg total RNA was used to synthesize 
first strand cDNA by the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, 
San Diego, California). The product of cDNA was amplified by PCR with specific primers for 
rat HO-1 exon 5 (CCC-TTC-CTG-TGT-CTT-CCT-TTG and ACA-GCC-GCC-TCT-ACC-
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GAC-CAC-A). The product of RT-PCR was separated using 1.5% agarose gel, and visualized 
by ethidium bromide. 
 
Western blots: 
Myocardial samples from LV, RV, and S were homogenized in Tris-HCl (13.2 
mM/L), glycerol (5.5%), SDS (0.44%), and β-mercaptoethanol. The same amount of soluble 
protein (50 µg) was fractionated by Tris-glycine-SDS-polyacrylamide gel (12%) 
electrophoresis, and Western blot was carried out as described by Pellacani et al [22] with the 
use of an antibody for recombinant rat HO-1 protein. 
 
Measurement of HO activity: 
Fifty milligrams of tissue were homogenized in 10 ml of 200 mM phosphate buffer, 
and then centrifuged at 19,000 x g 4 oC for 10 min. The supernatant was removed and 
recentrifuged at 100,000 x g 4 oC for 60 min, and precipitated fractions were suspended in 2 
ml of 100 mM K-phosphate buffer. Biliverdin reductase was crudely purified as described by 
Tenhunen et al.[23], and heme oxygenase activity was assayed as described by Yoshida et al., 
[24]. Reaction mixtures consisted of (final volume 2 ml) 100 µM K-phosphate (pH 7.4), 15 
nM hemin, 300 µM bovine serum albumin, 1 mg biliverdin reductase, and 1 mg microsomal 
fraction of cardiac tissue. The reaction was allowed to proceed for 1 h at 37 oC in dark in a 
shaking water bath and was stopped by placing the test on ice. Incubation mixtures were then 
scanned using a scanning spectrophotometer, and the amount of bilirubin was calculated as 
the difference between absorbance at 464 nm and 530 nm [25]. Proteins were determined by 
the method of Lowry et al.[26], in microsomal fractions. 
 
Measurement of CO: 
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Tissue CO content using gas chromatography was detected as described by Cook et al 
[27]. Briefly, hearts were homogenized in 4 volumes of 0.1 M phosphate-buffer (pH: 7.4) 
using an X520 homogenizer (Ingenieurburo CAT, M. Zipperer GmbH, Staufen, Germany). 
The homogenates were centrifuged at 4 oC for 15 min at 12,800 g and the supernatant 
fractions were used for the determination of tissue CO content. The reaction mixtures contain: 
150 µl of supernatant, 60 µl of NADPH (4.5 mM) and 50 µl of 3.5/0.35 mM methemalbumin, 
and for blank samples 60 µl phosphate buffer was used instead of NADPH. Samples were 
preincubated at 37 oC for 5 min, then the headspace was purged and the incubation was 
continued for 1 hour in dark at 37 oC. The reaction stopped by placing the samples on ice and 
the headspace gas was analyzed. One thousand µl of the headspace gas from each vial was 
injected into the gas chromatograph using a gastight syringe (Hamilton Co., USA) in 
hydrogen gas flow with a speed of 30 ml/min. Analysis took place during the next 150 
seconds on a 200 cm stainless-steel column with a 0.3 cm inner diameter. The detector was a 
thermal conductivity detector with an AC current of 80 mA. The individual value was 
expressed in mV. The column was packed with Molselect 5 Å and maintained at 30 oC. The 
temperature of the injector and detector was controlled and kept at 50 oC. 
 
Immunohistochemistry: 
Paraffin sections (7 µm) of tissue were incubated in the presence of polyclonal 
antibody and purified liver HO-1 obtained from rats (Stress Gen Biotech., Canada). Reactions 
were visualized by immunoperoxidase color reaction in NTg, HO-1 Tg, and HO-1 KO 
ischemic/reperfused mouse myocardium. Formalin fixed tissues were paraffin embedded and 
7 µm sections were placed on poly-l-lysine coated glass slides (Sigma, St.Luis, USA). 
Following deparaffinization and rehydration, samples were used for quenching endogenous 
peroxidases and blocking nonspecific binding sites by 3 % H2O2 in normal goat serum. 
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Sections were incubated for another 2 hours with HO-1 antibody at a dilution of 1:750 as 
described in the manufacturer’s manual. After 10 min of PBS washing, slides were incubated 
for additional 30 min in the presence of purified biotinylated anti/rabbit IgG (Vector, USA) at 
a dilution of 1:200. Slides were rewashed in PBS and incubated with peroxidase conjugated 
streptavidin (Zymed, USA) for 30 min followed by red color development using 3-amino-9-
ethylcarbazole in 0.1 M of acetate buffer (pH 5.2). Sections were counter-stained with Gill’s 
hematoxylin for 15-20 sec, rinsed with deionized water, and dipped in 1 % of lithium 
carbonate. After draining off water, slides were placed in oven for 30 min at 80 Co, and then 
covered with permount coverslips. Sections were photographed using a Zeiss (Germany) light 
microscope. 
 
Measurement of cellular Na+, K+, and Ca2+: 
Cellular cations were measured as previously described [28]. In brief, hearts were 
rapidly cooled to 0-5 oC by submersion in, and then perfused for 5 min with an ice-cold ion-
free buffer solution containing 100 mmol/L of trishydroxy-methyl-amino-methane and 220 
mmol/L of sucrose to wash out ions from the extracellular space and to stop enzyme activities 
responsible for membrane ion transport processes. Five minutes of cold washing of the heart 
washed out > 90 % of the ions from the extracellular space [29]. Following the wash out 
period, left ventricular tissues were dried for 48 hours at 100 oC, and made ash at 550 oC for 
20 hours. The ash was dissolved in 5 ml of 3 M nitric acid and diluted 10-fold with ion-free 
deionized water. Cellular Na+ was measured at a wavelength of 330.3 nm, K+ was measured 
at 404.4 nm, and Ca2+ at 422.7 nm in air-acetylene flame using an atomic absorption 
spectrophotometer (Perkin-Elmer 1100-B). This method for the measurement of cellular ion 
contents has been previously described in the myocardium [29,30] and central nervous system 
[31]. 
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Statistics: 
The data for HR, CF, AF, AOP, AOPdp/dt, cellular Na+, K+, Ca 2+, and infarct size were 
expressed as the MEAN ± SEM. One-way analysis of variance was first carried out to test for 
any differences between the mean values of groups. If differences were established the values of 
NTg group were compared to those of HO-1 transgenic, and HO-1 KO (-/-) groups by multiple t-
test followed by Bonferroni test. Because of the nonparametric distribution of the incidence of 
VF (sustained and nonsustained), the chi-square test was used to compare individual groups. A 
change of p<0.05 was considered to be statistically significant. 
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RESULTS 
For the confirmation of rat HO-1 expression at mRNA level, RT-PCR was used and total 
RNA was isolated from the nonischemic left and right ventricles, and septum of Tg and NTg 
littermates. The PCR product was rat HO-1 specific and was detected selectively in Tg mouse 
samples by RT-PCR (Fig. 2.A) and Western blot (Fig. 2.B). Under our experimental conditions, 
two clones were identified, and the fragment, the promoter, and HO-1 gene were excised by SfiI. 
Primers were amplified using 166-bp product originated from rat HO-1 exon 5. To avoid 
genomic DNA-based amplification, before the first stand cDNA synthesis, all biopsies were 
treated with DNase. The specific band was amplified in tissues obtained from left ventricle (LV), 
right ventricle (RV) , and septum (S), respectively, by PCR from RNA samples of Tg mouse 
from different lines (Fig. 2.A, Tg1: upper part, Tg2: middle part), but was absent in RNA 
samples of NTg (Fig.2.A, lower part). Tg1 and Tg2 proteins were also detected by Western blots 
in the LV, RV, and S of mouse hearts (Fig. 2.B upper and middle parts), but the expression of rat 
HO-1 proteins were absent in the NTg mouse myocardium (Fig. 2.B lower part).  
HO enzyme activities were also measured in the LV, RV, and S obtained from NTg and 
Tg mice (Fig. 2.C). The results show that HO activities were significantly increased in samples 
obtained from the LV, RV, and S of Tg mouse hearts in comparison with NTg values (Fig. 2.C) 
indicating the function of Tg1 and Tg2 genes in the mouse myocardium. It is important to note 
that HO-1 mRNA and protein were not detected in NTg mouse myocardium either by PCR (Fig. 
2.A lower part) or Western blot (Fig. 2.B lower part), but HO enzyme activities were present in 
the samples of NTg mouse myocardium including LV, RV, and S, respectively, indicating that 
measured HO enzyme activity involves all isoforms such as HO-1, HO-2, HO-3, and HO-4 (Fig. 
2.C). Thus, the differences in HO enzyme activities (Fig. 2.C) between NTg and Tg in the LV, 
RV, and S were clearly related to the rat HO-1 transgene in the mouse myocardium. 
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Table 1 shows the recovery of postischemic cardiac function in NTg and HO-1 Tg hearts 
subjected to 20 min of normothermic global ischemia followed by 2 hours of reperfusion. Before 
the induction of ischemia significant changes were not detected between NTg and HO-1 Tg 
groups in HR, CF, AF, AOP, and AOPdp/dt. Upon reperfusion, the postischemic recovery of CF, 
AF, AOP, and AOPdp/dt were observed in the HO-1 Tg group in comparison with the NTg 
values without any significant differences in HR. Thus, for instance, after 30 min and 120 min of 
reperfusion, AF was significantly increased from its NTg control values of 0.9 ± 0.1 ml/min and 
0.8 ± 0.1 ml/min  to 2.3 ± 0.2 ml/min (p<0.05) and 2.2 ± 0.2 ml/min (p<0.05) in the Tg group, 
respectively (Table 1). The same pattern was observed in the postischemic recovery in CF, AOP, 
and AOPdp/dt (Table 1). The results also show (Table 1) that 50 µmol/kg of SnPPIX, an HO 
enzyme inhibitor, abolished the postischemic recovery of cardiac function in comparison with 
the observed protection in the HO-1 Tg group. Thus, the values obtained in the HO-1 Tg + 
SnPPIX group were not statistically significant in comparison with the NTg values (Table 1). 
Figure 3 depicts representative curves of endogenous CO production detected by GC in 
NTg, Tg, and Tg SnPPIX treated myocardium subjected to 20 min ischemia followed by 120 
min of reperfusion. It is shown that in HO-1 Tg hearts subjected to 20 min of ischemia 
followed by 120 min of reperfusion (Fig. 3.B chromatogram), a substantial increase in CO 
production was observed in comparison with the NTg myocardium (Fig. 3. A chromatogram). 
However, the endogenous production of CO in the HO-1 Tg myocardium treated with 
SnPPIX was detected at relatively low level. (Fig. 3. C chromatogram) 
Figure 4 shows representative pictures of infarct size (Fig. 4. A, lower part, to the right) 
and immunohistochemical staining of HO-1 (Fig. 4. A, lower part to the left) in isolated 
mouse hearts subjected to ischemia and reperfusion. The infarct size (Fig. 4. A) was markedly 
reduced from its NTg control value of 37±4% to 20±6% (*p<0.05) in the HO-1 Tg group 
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(Fig. 4. A). However, in the HO-1 knock out hearts, the infarct size was significantly 
increased to 47±5% (*p<0.05) in comparison with NTg group (Fig. 4. A). 
In addition, Figure 4 A shows the representative immunohistochemical localization of 
HO-1 (Fig. 4. A, lower part, to the left) in NTg, Tg, and HO-1 KO ischemic/reperfused mouse 
hearts. Left ventricular cardiac samples were obtained from NTg, HO-1 Tg, and HO-1 KO 
mouse myocardium, respectively. Cytoplasmic protein staining (blue) of HO-1 in NTg 
myocardium was detected (Fig. 4. A, lower part, to the left) which was more intense in Tg 
myocardium, and markedly reduced in KO myocardium after 20 min of ischemia followed by 
120 min of reperfusion (Fig. 4. A lower part, to the left). 
Figure 4 also shows the incidence (%) of reperfusion-induced VF (Fig. 4 B) as total 
(sustained and nonsustained) and sustained VF in nontransgenic, transgenic, and knock out 
mouse groups. The incidence of reperfusion-induced total and sustained VF (Fig. 4 B) was 
significantly reduced from their nontransgenic (NTg) control values of 92% and 83% to 25% 
(*p<0.05) and 8% (*p<0.05), respectively, in the HO-1 Tg group. In the knock out group 
(Fig. 4 B), the incidence of reperfusion-induced total and sustained VF were 100% and 100%, 
respectively, showing the important role of HO-1 in arrhythmogenesis. 
Table 2 clearly shows that left ventricular tissue Na+, K+, and Ca2+ contents were not 
significantly varied between NTg, HO-1 Tg, and HO-1 Tg + SnPPIX groups before the 
induction of ischemia. However, the results (Table 2) also depict that left ventricular tissue 
Na+ and Ca2+ contents were significantly reduced after 20 min of ischemia followed by 120 
min of reperfusion in the HO-1 Tg group in comparison with the NTg and HO-1 Tg + 
SnPPIX values. In addition, the left ventricular tissue K+ content (Table 2) was significantly 
elevated (261±8 µmol/g dry weight, p<0.05) in the HO-1 Tg group compared to the K+ loss 
measured in the NTg group (229±5 µmol/g dry weight).  
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In hearts treated with SnPPIX, the ischemia/reperfusion resulted in the same 
maldistribution in cellular Na+, K+, and Ca2+ contents to those of the NTg group (Table 2). In 
other worlds, SnPPIX completely abolished the cardiac protection detected concerning the 
cellular Na+ and Ca2+ gains, and K+ loss in the HO-1 Tg group in the ischemic/reperfused 
myocardium. The values measured in the SnPPIX group were the same to the NTg mouse 
hearts (Table 2) after 20 min of ischemia followed by 120 min of reperfusion. 
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DISCUSSION 
 Myocardial ischemia/reperfusion-induced damage is a major cause of morbidity and 
mortality in the Industrialized Society, and considerable efforts have been made to target 
interventional therapies for this condition. In recent years, the concept of the modification in 
various gene expressions or repressions has emerged as new mechanisms and therapeutic 
tools for the induction of protection in ischemic/reperfused tissues. It is now also relatively 
well accepted that many human vascular diseases such as hypertension [32,33], heart failure 
[34-36], organ transplantation [9,37], and arrhythmias [38,39] can be treated with various 
interventions at a level of underlying genetic mechanisms. Several approaches have been 
made to manipulate cell phenotypes including the inhibition of genes associated with cell 
proliferation by preventing the development of atherosclerosis and restenosis [40-42] and the 
production of growth factors to promote angiogenesis [43-47] for the treatment of peripheral 
vascular disease and myocardial ischemia. 
 In our previous studies, we found a substantial reduction in the expression of HO-1 
mRNA and its protein with a causative reduction in the HO-1 enzyme activity in fibrillated 
ischemic/reperfused rat myocardium [13]. Moreover, we have shown that, in this respect, no 
difference exists between nondiabetic and diabetic heart [48]. Furthermore, HO-1 knock out 
mouse hearts displayed a reduced left ventricular function after ischemia/reperfusion [14]. If 
HO-1 system has a crucial role in the protection against ischemic/reperfusion-induced injury 
in the myocardium, with the enhanced expression of the HO-1, the more ischemic tissue can 
be salvaged. Therefore, in the present study, because of the HO-1 system can play a crucial 
role in the pathology of the ischemic/reperfused myocardium, we decided to approach the 
question from a different angle using HO-1 transgenic mouse hearts. 
 We generated HO-1 overexpressing Tg mice with an elevation in baseline HO enzyme 
activity by about 50% in the LV, RV, and S, respectively. Thus, the application of a genome-
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based transgene resulted in expression levels in relation with increased HO enzyme activities 
in comparison with those of HO activities levels detected in the LV, RV, and S obtained from 
NTg mice. Although, in our studies, the very similar homology between the mouse and rat 
HO-1 made it impossible to differentiate the HO-1 and Tg-induced enzyme activities, but we 
were able to distinguish them at mRNA level. In addition, our results obtained in NTg, HO-1 
Tg, and Tg-SnPPIX treated mouse hearts, we favor the idea that increased endogenous CO 
production levels in the myocardium represents the major signal transduction responsible for 
HO-1 related protection reflected in the improvement of the recovery in postischemic cardiac 
function, reduction of the incidence of reperfusion-induced VF and infarct size connected to 
the recovery of cellular ion contents. Our results further supported by the complete loss of 
cardiac protection in the Tg ischemic/reperfused mice treated with SnPPIX, the inhibitor of 
HO enzyme. 
The exact mechanism by which HO-1 induces cardiac protection remains to be 
elucidated, however, one of the most significant protective mechanisms of the HO system can 
be explained by the generation of endogenous CO and its signaling mechanism. CO could 
suppress cell apoptosis [37] suggesting that the antiapoptotic effect of HO-1 is mediated via 
the generation of CO. In addition, anti-inflammatory property of CO suppresses the 
expression of proinflammatory genes associated with the activation of monocyte/Mф [49]. 
Another possible cellular signaling mechanism of CO is associated with the guanylyl 
cyclase activation and tissue levels of cGMP and cAMP in isolated ischemic/reperfused 
myocardium [50]. Very low concentrations of CO, in the perfusion buffer, afford a significant 
protection against the ischemia/reperfusion-induced damage in isolated buffer perfused hearts. 
The isolated buffer perfused heart could be an ideal model to study the direct effect of 
exogenous CO on cardiac function and molecular signaling because the blood and its 
elements are excluded from the model, thus the oxygen transport to cells and tissues is not 
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directly damaged via the CO/blood/haemoglobin system. Previous results have shown that 
low concentrations of exogenous CO protect the isolated ischemic/reperfused myocardium 
and act by increasing tissue cAMP and cGMP levels [50]. Indeed, a moderate increase in 
cAMP content could lead to arrhythmogenesis and development of various arrhythmias by 
elevating cytosolic calcium levels [51] in the ischemic and postischemic myocardium. It is of 
interest to note that multiple increases in cGMP levels could mask and interfere with the 
arrhythmogenic effects of cAMP leading to the suppression of reperfusion-induced VF in the 
myocardium [50]. The significant increase in cGMP levels can be related to guanylate cyclase 
activities in CO-treated myocardium, and suggests that induction of guanylate cyclase-cGMP 
system via CO signaling is essential for cardioprotection in ischemic/reperfused hearts. 
However, not only the absolute levels of cGMP and cAMP are the critical factors after 
ischemia and reperfusion that determine the recovery of postischemic cardiac function, but 
also the ratio of these two nucleotides [52]. Thus, the lower cAMP/cGMP ratio during 
ischemia, the better the postischemic cardiac recovery is achieved in isolated 
ischemic/reperfused hearts. 
“It has to be noted, that Lakkisto et al., have recently found that cadioprotection 
induced by hemin, a well known inducer of hemoxigenase 1, is independent of cGMP levels 
and, at least by part, being mediated via the preservation of Cx43 [53]. They found that 
elevated HO-1 levels, induced by hemin, are not accompanied by elevated cGMP levels. In 
our previous study [50], we have found that cGMP levels are elevated after exogenous CO 
application, moreover, after exogenous CO administration the ratio of cAMP/cGMP is 
reduced. In their study [53] the authors measured only the level of cGMP and not the ratio of 
cAMP/cGMP. The difference between their and our results is probably due to the higher CO 
concentration after the exogenous administration.  
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Although not specifically studied in the present investigation at molecular level, it is of 
interest to note the findings of Piantadosi et al. [54] with myocardial cells. In their studies, 
Piantadosi et al., implicated the role of HO-1/CO pathway in mitochondrial biogenesis 
through Akt1 activation [55] involving Nrf2 expression, downstream GSK3β blockade, and 
Nrf2 nuclear translocation leading to Nrf2-dependent activation of NRF-1 transcription. Their 
finding suggest HO-1/CO , by sequentially activating the aforementioned two transcription 
factors, as a remarkable component of a prosurvival program of mitochondrial biogenesis 
connected to cellular antioxidant defense mechanisms [56,57]. 
Today, when so many advances and efforts are being made in molecular biology and 
genetics, we tend to lose sight of the importance of basic ions such as Na+, K+, and Ca2+ in 
both clinical and experimental studies. As a gap, in changes between various gene expression 
and/or repression and the function of myocardial tissue, could closely be connected with 
changes in myocardial tissue ion contents. An important finding such a final endpoint of our 
present study was the myocardial “K+ – conserving effect” related to the prevention of 
cellular Na+ and Ca2+ gains in Tg myocardium, and this cardiac protection can be reversed by 
SnPPIX, an HO-1 inhibitor. HO-1 – bilirubin system and one of its byproduct, CO, are 
essential for regulation of cardiac function and ion transport across cell membranes via the 
stabilization of various Na, K, and Ca ion channels possibly by an effect exerted on Na-K-
ATPase, and these transient outward and inward currents are thought to underline the delayed 
after depolarization that can be observed after the action potential in Ca-loaded cardiac tissue 
propagating rhythm disturbances [58]. There are significant differences in the cellular 
signaling mechanisms induced by CO when they are compared with the actions of other 
interventions that elevate cyclic nucleotides in tissues. CO has been proposed to increase KCa 
channel Ca2+ sensitivity in arterial smooth muscle cells [59], and the data of Perez et al., [60] 
suggest that CO increases Ca2+ spark coupling by shifting the Ca2+ sensitivity of KCa channels 
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produced by Ca2+ sparks. Thus, CO may act KCa channel beta subunits to enhance the 
coupling relationship leading to cellular K+ loss, and Ca2+ and Na+ gains as we observed in 
our present studies. 
In our study we have shown that CO level was significantly increased in the HO-1 Tg 
mouse myocardium. However, we did not measure CO levels during reperfusion, therefore, 
we believe that the elevated CO production can be responsible for the protection during 
reperfusion in Tg myocardium. Beside this, we cannot rule out the contribution of other HO-1 
related molecules such as biliverdin and bilirubin to the observed cardiac protection. 
In conclusion, using HO-1 transgenic mice, we have demonstrated the direct causative 
role of HO-1 in protection against ischemia/reperfusion-induced injury. Specifically, our 
results show a significant recovery of postischemic cardiac function, prevention of the 
development of reperfusion-induced VF, and reduction in infarct size. In addition, we have 
provided new insights into the ionic mechanisms by which HO-1 may contribute to the 
attenuation of reperfusion-induced arrhythmias in HO-1 transgenic mice. We believe that 
these studies would help in developing novel therapies based on targeting HO-1 for the 
treatment of ischemia/reperfusion injury in patients with coronary artery disease. 
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LEGENDS FOR FIGURES: 
Fig. 1. Schematic presentation of the experimental time course. 
Fig. 2. The detection of rat HO-1 transgene by PCR (A) and Western blot (B), and HO 
enzyme activities ( C ) in mouse hearts. Total RNA obtained from mouse left ventricle (LV), 
right ventricle (RV), and septum (S), respectively, was used to synthesize first strand cDNA. 
HO-1 originated from rat was amplified by PCR exon 5-specific primer and visualized with 
ethidium bromide as a 166-bp band by agarose gel electrophoresis. In two clones, the specific 
band was amplified from RNA samples of RV, LV, and S, respectively, in transgene 
(transgene 1 and transgene 2) mice (A, upper and middle parts), but it was absent in the RNA 
sample of NTg littermate (A, lower part). Western blots (B) also depict the expression of rat 
transgene 1, transgene 2, and NTg in the LV, RV, and S of mouse hearts. HO enzyme 
activities are also shown in the LV, RV, and S in NTg and Tg myocardium ( C ). n=6 in each 
group, MEAN ± SEM, *p<0.05, comparisons were made to the NTg values in each group. 
 
Fig. 3. Representative GC chromatograms for the demonstration of endogenous CO 
production in nontransgenic (NTg, chromatogram a), HO-1 transgenic (HO-1 Tg, 
chromatogram b), and HO-1 Tg mouse myocardium treated with SnPPIX (HO-1 Tg + 
SnPPIX, chromatogram c). Hearts were subjected to 20 min of normothermic global ischemia 
followed by 120 min of reperfusion. The results show, in NTg myocardium (chromatogram 
a), that there is a well detectable endogenous CO production after 20 min of ischemia 
followed by 120 min of reperfusion. The endogenous CO production was substantially 
increased in HO-1 Tg myocardium (chromatogram b), and a reduction of endogenous CO 
production was recorded in HO-1 myocardium treated with SnPPIX (chromatogram c). 
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Fig. 4. Infarct size and HO-1 staining in isolated nontransgenic (NTg), transgenic (Tg), and 
HO-1 knock out (KO) mouse hearts subjected to 20 min of normotermic global ischemia 
followed by 120 min of reperfusion. * p<0.05 compared to the NTg control values. n=6 in 
each group. Infarct is represented by white area surrounding by the living red tissues (A, to 
the right lower part). Immunochemical localization of HO-1 is stained by blue in NTg, Tg and 
KO myocardium (A, to the left lower part). B shows the incidence (%) of total (open bars) 
and sustained (hatched bars) reperfusion-induced VF in isolated NTg, Tg, and KO mouse 
hearts. The incidence of reperfusion-induced VF was registered, and comparisons were made 
to the values of NTg group. n=12 in each group, *p<0.05. Because of the nonparametric 
distribution in the incidence of total and sustained VF, the chi-square nonparametric test was 
used to compare individual groups. This Figure was presented at the FEAM Meeting held in 
Bucharest, Rumania, in March, 2010, and published in the May issue of the JCMM, 2010, as the 
Proceedings of the Meeting. 
 
 
Table 1. Effects of 20 min of ischemia followed by 30 min and 120 min of reperfusion on the recovery of cardiac function in none transgenic (NTg) and 
HO-1 transgenic mice (Tg), and the effect of SnPPIX. 
 
 
 B e f o r e I s c h e m i a    A f t e r  r e p e r f u s i o n (RE) 
     30 min       120 min 
 HR CF AF AOP AOPdp/dt HR CF AF AOP AOPdp/dt HR CF AF AOP AOPdp/dt 
NTg 288±9 3.0±0.2 3.5±0.2 157±7 3794±73 255±9 2.0±0.1 0.9±0.1 72±6 945±44 262±9 2.1±0.1 0.8±0.1 67±4 930±51 
HO-1 Tg 292±8 3.2±0.3 3.4±0.2 149±6 3834±85 261±7 2.8±0.1* 2.3±0.2* 95±7* 2000±63* 269±8 2.9±0.2* 2.2±0.2* 91±6* 1880±80* 
HO-1 Tg 
+ SnPPIX 
294±9 3.1±0.2 3.2±0.3 152±9 3815±94 265±8 2.2±0.2 1.1±0.2 78±7 1018±80 270±9 2.0±0.3 1.1±0.2 72±8 1000±77 
 
 
n= 6 in each group, MEAN ± SEM, Heart rate (HR, beats/min), Coronary flow (CF, ml/min), Aortic flow (AF, ml/min), Aortic pressure (AOP, mmHg), 
First derivative of aortic pressure (AOPdp/dt, mmHg/s). Tin protoporphyrin IX (SnPPIX). *p< 0.05, comparisons were made to the time-matched none 
transgenic NTg values. 
 
 
 
Table 2. Cellular Na+, K+, and Ca2+ contents (µmol/g dry weight) in the left ventricular tissue before ischemia and after 20 min of ischemia 
followed by 120 min of reperfusion in none transgenic (NTg) and HO-1 transgenic mice (Tg), and the effect of SnPPIX. 
 
 
 
Group 
 
Before  ischemia 
 
After 20 min ISA followed by 120 min RE 
  
Na+ 
 
K+ 
 
Ca2+ 
 
Na+ 
 
K+ 
 
Ca2+ 
 
NTg 
 
31±3 
 
282±6 
 
1.6±0.1 
 
84±5 
 
229±5 
 
4.1±0.3 
 
HO-1 Tg 
 
27±4 
 
277±7 
 
1.7±0.2 
 
58±7* 
 
261±8* 
 
2.5±0.5* 
 
HO-1 Tg + SnPPIX 
 
35±5 
 
286±9 
 
1.9±0.3 
 
90±9 
 
219±9 
 
4.5±0.7 
 
n= 6 in each group, MEAN ± SEM, *p< 0.05, comparisons were made to the time-matched none transgenic (NTg) values. Tin protoporphyrin IX 
(SnPPIX). Ischemia (ISA), Reperfusion (RE). 
 




